---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-057420"
form_type: "8-K"
ticker: "RANI"
cik: "0001856725"
company_name: "Rani Therapeutics Holdings, Inc."
filed_at: "2023-11-01T23:59:59+00:00"
generated_at: "2026-06-09T03:15:25.086424+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Rani Therapeutics cuts workforce 25%, extends cash runway into 2025; reports preliminary Q3 net loss $17-19M

## Summary
- Workforce reduced ~25%; restructuring cost ~$0.3M (nearly all cash) expected Q4 2023, complete by Q1 2024.
- Cash, cash equivalents and marketable securities ~$60.5M at Sept 30, 2023; cash runway extended into 2025.
- Preliminary Q3 net loss $17-19M (vs $16.2M in Q3 2022); nine-month net loss $53-55M.
- RT-102 Phase 2 starts Q4 2023; RT-111 Phase 1 topline Q1 2024; RaniPill HC Phase 1-ready H2 2024.
- RT-101 discontinued; RT-105 and RT-110 paused; new 33,340 sq ft lease in Fremont at $95,019/month base rent.

## SEC filing metadata
- accession: 0000950170-23-057420
- form_type: 8-K
- ticker: RANI
- cik: 0001856725
- company_name: Rani Therapeutics Holdings, Inc.
- filed_at: 2023-11-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.02, 2.05, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1856725/000095017023057420/0000950170-23-057420-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1856725/000095017023057420/rani-20231101.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-057420
- JSON: https://secwatch.observer/filing/0000950170-23-057420.json
- Plain text: https://secwatch.observer/filing/0000950170-23-057420.txt

## Key facts
- Earnings Releases
  Rani Therapeutics Holdings, Inc. reported the third quarter ended September 30, 2023 results: net income between $17.0 million and $19.0 million.
  - Period: the third quarter ended September 30, 2023
  - Net income: between $17.0 million and $19.0 million
  - Result: preliminary results
  source text: Rani’s preliminary consolidated financial results for the third quarter ended September 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1856725/000095017023057420/0000950170-23-057420-index.htm
- Material Agreements
  Rani Therapeutics Holdings, Inc. entered into Standard Industrial/Commercial Multi-Tenant Lease - Net with BKM South Bay 240, LLC valued at $95,019.00 per month (effective 2023-11-01).
  - Action: entry
  - Agreement: lease
  - Counterparty: BKM South Bay 240, LLC
  - Value: $95,019.00 per month
  - Effective: 2023-11-01
  source text: On November 1, 2023, Rani Therapeutics, LLC (“Rani LLC”), a subsidiary of Rani Therapeutics Holdings, Inc. (the “Company”), and BKM South Bay 240, LLC (“Landlord”) entered into the Standard Industrial/Commercial Multi-Tenant Lease - Net (the “Lease”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1856725/000095017023057420/0000950170-23-057420-index.htm
- Restructurings & Charges
  Rani Therapeutics Holdings, Inc. announced a restructuring with charges of approximately $0.3 million (reduction of the Company’s workforce by approximately 25%).
  - Type: restructuring
  - Charge: approximately $0.3 million
  - Headcount: reduction of the Company’s workforce by approximately 25%
  source text: On November 1, 2023, the Company committed to the Restructuring, which is a plan for strategic prioritization of its programs, expansion of its manufacturing and streamlining of its business operations to support potential near-term value drivers and long-term growth. The Restructuring provides for a reduction of the Company’s workforce by approximately 25%. As a result of the Restructuring, the Company estimates that it will incur approximately $0.3 million in costs of which nearly all are cash expenditures related to severance.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1856725/000095017023057420/0000950170-23-057420-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.